Side-by-side · Research reference
DSIPvsLiraglutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticDraft8/36 cited
BFDA-ApprovedVerified14/45 cited
DSIP
Sleep modulator · Anti-stress
SQ · Pre-sleep · Daily during cycle
Liraglutide
Daily GLP-1 RA · FDA-Approved
SQ · Abdomen / thigh / arm · Once daily
01Mechanism of Action
Parameter
DSIP
Liraglutide
Primary target
Multiple — modulates HPA axis + thalamic delta-wave generation (proposed)Schneider 1986
GLP-1 receptor (GLP-1R)SAXENDA (liraglutide) injectio 2014
Pathway
Reduced cortisol/ACTH + enhanced delta-wave EEG activity → improved sleep onset + depthSchneider 1986
GLP-1R agonism → ↑glucose-dependent insulin, ↓glucagon, ↓gastric emptying, ↓appetiteSAXENDA (liraglutide) injectio 2014Marso 2016
Downstream effect
Faster sleep onset, increased delta sleep, reduced stress response, possible anxiolytic effectSchneider 1986
Glycemic improvement, modest body-weight reduction, cardiovascular event reduction in high-risk T2DMarso 2016
Feedback intact?
—
Glucose-dependent insulin release preserves physiological feedback
Origin
Endogenous peptide first isolated from rabbit blood during delta sleep; synthesised exogenouslySchneider 1986
Modified GLP-1(7-37) with Lys26 substitution (Arg34) and C-16 palmitoyl-glutamate acylation for albumin bindingSAXENDA (liraglutide) injectio 2014
Antibody development
—
—
02Dosage Protocols
Parameter
DSIP
Liraglutide
Frequency
Once daily, pre-sleep
Once daily, same time each day
Lower / starter dose
50 mcg pre-sleep
—
Evidence basis
Human-mechanistic + early clinicalSchneider 1986
FDA-approved · Phase 3 RCTs (LEADER, SCALE)Marso 2016SAXENDA (liraglutide) injectio 2014
Duration
8–12 weeks per cycle
Indefinite for chronic indication
Reconstitution
Bacteriostatic water
Pre-filled commercial pen (no reconstitution)
Timing
30–60 min pre-sleep
Any time of day; consistent
Standard dose (weight, Saxenda)
—
3.0 mg / day (after 5-week titration)SAXENDA (liraglutide) injectio 2014
Titration schedule
—
0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg over 5 weeks
Mitigates GI side effects.
04Side Effects & Safety
Parameter
DSIP
Liraglutide
Injection site reaction
Mild irritation
—
Drowsiness
Expected effect (intentional)
—
Vivid dreams
Anecdotally reported
—
Long-term safety
Limited modern RCT data
—
Pregnancy / OB
Avoid
Contraindicated
GI symptoms
—
Nausea, vomiting, diarrhea (very common during titration)SAXENDA (liraglutide) injectio 2014
Pancreatitis risk
—
Rare; discontinue if suspected
Thyroid C-cell tumours
—
Boxed warning — contraindicated in MEN2 / MTC historySAXENDA (liraglutide) injectio 2014
Hypoglycemia
—
Low risk as monotherapy; elevated with sulfonylureas / insulin
Heart rate
—
Modest ↑ resting HR (~2-3 bpm)
Absolute Contraindications
DSIP
- ·Pregnancy / breastfeeding
- ·Concurrent CNS-depressant therapy without supervision
Liraglutide
- ·MTC personal or family history; MEN2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to liraglutide
Relative Contraindications
DSIP
- ·Severe sleep apnoea (untreated)
- ·Concurrent benzodiazepine / opioid use
Liraglutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Severe gastrointestinal disease
05Administration Protocol
Parameter
DSIP
Liraglutide
1. Reconstitution
Add 1–2 mL bacteriostatic water to vial.
Commercial pre-filled pen, no reconstitution required.
2. Injection site
SQ — abdomen. Rotate sites.
SQ — abdomen, thigh, or upper arm. Rotate sites.
3. Timing
30–60 min pre-sleep.
Once daily, same time each day. Take with or without food.
4. Storage
Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.
Refrigerate 2–8 °C unopened; room temp ≤30 °C up to 30 days after first use.
5. Needle
29–31G insulin syringe.
Pen-supplied 32G needle.